These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18520602)

  • 1. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
    Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
    Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
    Moltó J; Valle M; Blanco A; Negredo E; DelaVarga M; Miranda C; Miranda J; Domingo P; Vilaró J; Tural C; Costa J; Barbanoj MJ; Clotet B
    Clin Pharmacokinet; 2007; 46(1):85-92. PubMed ID: 17201460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
    Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
    Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
    Khaykin P; Kotzerke P; Stephan C; Nisius G; Bickel M; Haberl A; Stürmer M; Kurowski M; Brodt R; von Hentig N
    Ther Drug Monit; 2014 Apr; 36(2):192-201. PubMed ID: 24632753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
    Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir protein binding in vivo through the 12-hour dosing interval.
    Boffito M; Hoggard PG; Lindup WE; Bonora S; Sinicco A; Khoo SH; Di Perri G; Back DJ
    Ther Drug Monit; 2004 Feb; 26(1):35-9. PubMed ID: 14749547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
    Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; García Cabanillas JA; DaSilva B; Brun SC; Arribas J
    J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced lopinavir exposure during pregnancy.
    Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
    AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
    Cressey TR; Jourdain G; Rawangban B; Varadisai S; Kongpanichkul R; Sabsanong P; Yuthavisuthi P; Chirayus S; Ngo-Giang-Huong N; Voramongkol N; Pattarakulwanich S; Lallemant M;
    AIDS; 2010 Sep; 24(14):2193-200. PubMed ID: 20625263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L
    Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
    Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
    Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    Chadwick EG; Capparelli EV; Yogev R; Pinto JA; Robbins B; Rodman JH; Chen J; Palumbo P; Serchuck L; Smith E; Hughes M;
    AIDS; 2008 Jan; 22(2):249-55. PubMed ID: 18097227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
    Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.